Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03499483 · ClinicalTrials.gov registry record · Phase 4
Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)
A Phase 4 study, sponsored by Fenway Community Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT03499483: Completed Phase 4 study, sponsored by Fenway Community Health.
NCT03499483 is a Phase 4 study that has completed, run by Fenway Community Health. The registered enrollment target is 52 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03499483, a Phase 4 study, has completed, sponsored by Fenway Community Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
Study will evaluate the safety and tolerability of once daily Biktarvy for 28 days for prevention of HIV infection in HIV-1-seronegative adults after high-risk sexual contact. (non-occupational post exposure prophylaxis - nPEP)
Primary Outcome
HIV sero-conversion during study participation following high risk exposure that occured within 72 hours of study product initiation.
Interventions
- DRUG bictegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-01-24 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 4 |
What the finished NCT03499483 record still lists
NCT03499483 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which bictegravir is the first listed.
NCT03499483 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03499483 about?
NCT03499483 is a clinical study titled "Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)". Study will evaluate the safety and tolerability of once daily Biktarvy for 28 days for prevention of HIV infection in HIV-1-seronegative adults after high-risk sexual contact. (non-occupational post exposure prophylaxis - nPEP)
What is the current status of trial NCT03499483?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2019-01-24. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT03499483?
The interventions under investigation include: bictegravir (DRUG).
Who is sponsoring clinical trial NCT03499483?
This trial is sponsored by Fenway Community Health, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03499483's enrollment target sits among peer trials
52 1233rd of 2000 higher than 752 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI